Targeting Androgen Receptor Activity in Prostate Cancer
Targeting Androgen Receptor Activity in Prostate Cancer
批准号:
7229925
负责人:
MATTHEW B RETTIG
金额:
$9.17万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2009-01-31
关键词:
Androgen ReceptorAndrogen Response ElementAndrogensAntiandrogen TherapyApoptosisBindingCancer EtiologyDNA Binding DomainDataDevelopmentDiseaseEctopic ExpressionEnvironmentFutureGene AmplificationGene SilencingGene TargetingGenesGenetic TranscriptionGrowthHumanIn VitroInduction of ApoptosisInhibition of ApoptosisLengthLigand Binding DomainMalignant neoplasm of lungMalignant neoplasm of prostateNeoplasm MetastasisPathway interactionsPatientsPharmaceutical PreparationsProtein OverexpressionRNA InterferenceReceptor GeneReportingRoleSkin CancerSolid NeoplasmTransactivationbasecancer cellcancer diagnosisdeprivationin vivoinhibitor/antagonistmenmortalitymutantpreventsmall moleculetranscription factortumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Prostate cancer (PCa) is the second leading cause of mortality amongst U.S. men. PCa is initially androgen-dependent (AD) and anti-androgen therapy is effective in virtually all patients. Unfortunately, patients develop and eventually succumb to androgen-independent disease, at which point PCa tumors continue to grow and metastasize despite castrate levels of androgen. A growing body of evidence has established that sustained growth of Al PCa is dependent upon continued expression and activation of the androgen receptor (AR). Because the primary function of the AR is to serve as a transcription factor that binds to the androgen response element (ARE) in target genes that inhibit apoptosis and promote proliferation, we hypothesize that inhibition of the transcriptional activity of the AR will result in diminished growth of Al PCa. Our overall objective is to provide proof-of-principle evidence that inhibition of AR transcriptional activity by blocking the AR-ARE interaction will retard human Al PCa growth in vitro and in vivo. This evidence will be the basis for future studies to identify small molecule inhibitors of AR transcriptional activity by interfering with the AR-ARE interaction. Thus, our long-term objective is to develop a drug to specifically block AR transcriptional activity that could potentially be used to treat patients with Al prostate cancer. For the current application, our principal strategy to block binding of the AR to its cognate ARE involves the ectopic expression of a deletion mutant of the AR, which contains the AR DNA binding domain (DBD), but lacks both the transactivation domain (TAD) and ligand binding domain (LBD). We and others have shown that AR-DBD constructs have been shown to inhibit the transcriptional activity of the full-length AR. Using this strategy, we propose the following specific aims: 1) Establish that expression of the AR-DBD inhibits the transcriptional activity of the AR by preventing the AR-ARE interaction, and 2) Demonstrate that inhibition of the AR-ARE interaction results in reduced growth of Al PCa both in vitro and in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
-
批准号:10917011
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:MATTHEW B RETTIG
-
依托单位:
A Phase 2 study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
-
批准号:10417047
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:MATTHEW B RETTIG
-
依托单位:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
-
批准号:9487898
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MATTHEW B RETTIG
-
依托单位:
HIF-alpha-independent Druggable Targets in Renal Cell Carcinoma
-
批准号:8921769
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2015
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8551641
-
项目类别:
-
资助金额:$24.58万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:9097575
-
项目类别:
-
资助金额:$26.15万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8699713
-
项目类别:
-
资助金额:$25.36万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8912402
-
项目类别:
-
资助金额:$26.15万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Identification of Inhibitors of the N-Terminal Region of the Androgen Receptor
-
批准号:8373260
-
项目类别:
-
资助金额:$26.15万
-
财政年份:2012
-
负责人:MATTHEW B RETTIG
-
依托单位:
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
-
批准号:8413407
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:MATTHEW B RETTIG
-
依托单位:
Targeting HPV E6-Dependent Hypoxia-Induced NF-kappa B in Cervical Cancer
-
批准号:7927183
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:MATTHEW B RETTIG
-
依托单位:
Targeting Androgen Receptor Activity in Prostate Cancer
-
批准号:7030446
-
项目类别:
-
资助金额:$9.44万
-
财政年份:2006
-
负责人:MATTHEW B RETTIG
-
依托单位:
Increased IL6 Transcription by HHV8
-
批准号:6430782
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Increased IL6 Transcription by HHV8
-
批准号:6726106
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10000845
-
项目类别:
-
资助金额:$27.18万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10704572
-
项目类别:
-
资助金额:$24.61万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10478982
-
项目类别:
-
资助金额:$30.33万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Project 2: Developing an N-terminal inhibitor of the androgen receptor
-
批准号:10246998
-
项目类别:
-
资助金额:$29.74万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Increased IL6 Transcription by HHV8
-
批准号:6621178
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
Increased IL6 Transcription by HHV8
-
批准号:7022276
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2002
-
负责人:MATTHEW B RETTIG
-
依托单位:
海外基金